Resiniferatoxin
Resiniferatoxin is a small molecule pharmaceutical. It is currently being investigated in clinical studies. It is known to target voltage-gated potassium channel KCNC1, potassium voltage-gated channel subfamily A member 2, potassium voltage-gated channel subfamily A member 5, transient receptor potential cation channel subfamily V member 1, potassium voltage-gated channel subfamily A member 7, and potassium voltage-gated channel subfamily A member 1.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
No data
Clinical
Clinical Trials
96 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Kidney diseases | D007674 | EFO_0003086 | N08 | — | — | — | 1 | 3 | 4 |
| Thrombocytopenic purpura idiopathic | D016553 | EFO_0007160 | D69.3 | — | — | 2 | 1 | — | 3 |
| Systemic lupus erythematosus | D008180 | EFO_0002690 | M32 | 1 | — | 1 | 1 | — | 3 |
| Rheumatoid arthritis | D001172 | EFO_0000685 | M06.9 | — | — | 1 | 2 | — | 3 |
| Neuromyelitis optica | D009471 | EFO_0004256 | G36.0 | — | — | — | 1 | 1 | 2 |
| Anti-neutrophil cytoplasmic antibody-associated vasculitis | D056648 | — | I77.82 | — | — | — | 1 | 1 | 2 |
| Glomerulonephritis | D005921 | — | N05 | — | — | — | 2 | — | 2 |
| Graves ophthalmopathy | D049970 | EFO_1001466 | — | — | — | — | 1 | — | 1 |
| Autoimmune diseases | D001327 | EFO_0000540 | M30-M36 | — | — | — | 1 | — | 1 |
| Respiratory insufficiency | D012131 | — | J96.9 | — | — | — | 1 | — | 1 |
Show 11 more
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Knee osteoarthritis | D020370 | EFO_0004616 | M17 | 2 | 1 | 3 | — | — | 6 |
| Osteoarthritis | D010003 | EFO_0002506 | M15-M19 | — | 1 | 5 | — | — | 6 |
| Large b-cell lymphoma diffuse | D016403 | — | C83.3 | 3 | 4 | 2 | — | — | 5 |
| Cancer pain | D000072716 | — | G89.3 | 3 | 2 | 1 | — | — | 5 |
| Glioblastoma | D005909 | EFO_0000515 | — | 1 | 2 | 1 | — | — | 4 |
| Intractable pain | D010148 | — | — | 2 | 2 | 1 | — | — | 4 |
| Myocardial infarction | D009203 | EFO_0000612 | I21 | — | 1 | 1 | — | 3 | 4 |
| Infarction | D007238 | EFO_0009463 | — | — | 1 | 1 | — | 3 | 4 |
| Lymphoma | D008223 | — | C85.9 | — | 2 | 2 | — | 1 | 3 |
| Membranous glomerulonephritis | D015433 | EFO_0004254 | N03.2 | — | 1 | 1 | — | 2 | 3 |
Show 15 more
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| B-cell chronic lymphocytic leukemia | D015451 | — | C91.1 | 2 | 2 | — | — | — | 4 |
| Nephrotic syndrome | D009404 | EFO_0004255 | N04 | — | 4 | — | — | — | 4 |
| Rectal neoplasms | D012004 | — | — | — | 3 | — | — | — | 3 |
| Epstein-barr virus infections | D020031 | EFO_0000769 | — | — | 1 | — | — | 1 | 2 |
| Recurrence | D012008 | — | — | 1 | 1 | — | — | — | 2 |
| Chronic renal insufficiency | D051436 | — | N18 | — | 1 | — | — | 1 | 2 |
| Follicular lymphoma | D008224 | — | C82 | 2 | 1 | — | — | — | 2 |
| Palliative care | D010166 | — | — | 2 | 1 | — | — | — | 2 |
| Pain | D010146 | EFO_0003843 | R52 | 1 | 1 | — | — | — | 2 |
| Kidney transplantation | D016030 | — | — | — | 1 | — | — | — | 1 |
Show 22 more
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Neoplasms | D009369 | — | C80 | 1 | — | — | — | 2 | 3 |
| Non-hodgkin lymphoma | D008228 | — | C85.9 | 1 | — | — | — | 1 | 2 |
| Hodgkin disease | D006689 | — | C81 | 1 | — | — | — | 1 | 2 |
| Brain neoplasms | D001932 | EFO_0003833 | C71 | 1 | — | — | — | — | 1 |
| Colorectal neoplasms | D015179 | — | — | 1 | — | — | — | — | 1 |
| Hyperthermic intraperitoneal chemotherapy | D000084262 | — | — | 1 | — | — | — | — | 1 |
| Arthralgia | D018771 | — | M25.5 | 1 | — | — | — | — | 1 |
| Morton neuroma | D000070607 | — | G57.6 | 1 | — | — | — | — | 1 |
| Gout | D006073 | EFO_0004274 | M10 | 1 | — | — | — | — | 1 |
| Sarcoma | D012509 | — | — | 1 | — | — | — | — | 1 |
Show 2 more
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| St elevation myocardial infarction | D000072657 | — | — | — | — | — | — | 2 | 2 |
| Infections | D007239 | EFO_0000544 | — | — | — | — | — | 1 | 1 |
| Communicable diseases | D003141 | — | — | — | — | — | — | 1 | 1 |
| Intubation | D007440 | — | — | — | — | — | — | 1 | 1 |
| Heart failure | D006333 | EFO_0003144 | I50 | — | — | — | — | 1 | 1 |
| Angina pectoris | D000787 | EFO_0003913 | I20 | — | — | — | — | 1 | 1 |
| Coronary stenosis | D023921 | EFO_1000882 | — | — | — | — | — | 1 | 1 |
| Pathologic constriction | D003251 | — | — | — | — | — | — | 1 | 1 |
| Mitral valve stenosis | D008946 | EFO_0007372 | — | — | — | — | — | 1 | 1 |
| Covid-19 | D000086382 | — | U07.1 | — | — | — | — | 1 | 1 |
Show 16 more
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Resiniferatoxin |
| INN | resiniferatoxin |
| Description | Resiniferatoxin (RTX) is a naturally occurring chemical found in resin spurge (Euphorbia resinifera), a cactus-like plant commonly found in Morocco, and in Euphorbia poissonii found in northern Nigeria. It is a potent functional analog of capsaicin, the active ingredient in chili peppers.
|
| Classification | Small molecule |
| Drug class | fluoroquinolone derivatives, nonantibacterial indication (e.g., antineoplastic antibiotics) |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | C=C(C)[C@]12C[C@@H](C)[C@@]34O[C@](Cc5ccccc5)(O[C@@H]1[C@@H]3C=C(COC(=O)Cc1ccc(O)c(OC)c1)C[C@]1(O)C(=O)C(C)=C[C@H]14)O2 |
Identifiers
| PDB | — |
| CAS-ID | 57444-62-9 |
| RxCUI | — |
| ChEMBL ID | CHEMBL17976 |
| ChEBI ID | — |
| PubChem CID | 104826 |
| DrugBank | DB06515 |
| UNII ID | A5O6P1UL4I (ChemIDplus, GSRS) |
Target
Agency Approved
No data
Alternate
KCNC1
KCNC1
Organism
Homo sapiens
Gene name
KCNC1
Gene synonyms
NCBI Gene ID
Protein name
potassium voltage-gated channel subfamily C member 1
Protein synonyms
NGK2, potassium channel, voltage gated Shaw related subfamily C, member 1, voltage-gated potassium channel protein KV3.1, Voltage-gated potassium channel subunit Kv3.1, Voltage-gated potassium channel subunit Kv4
Uniprot ID
Mouse ortholog
Kcnc1 (16502)
potassium voltage-gated channel subfamily C member 1 (P15388)
Variants
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 36,487 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
10 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use